Earnings To Watch: Longeveron Inc (LGVN) Reports Q3 2024 Result

Longeveron Inc (LGVN) reported its financial results for the three and nine months ended September 30, 2024.

The company reported a net loss of $16.2 million, or $0.27 per share, for the three months ended September 30, 2024, compared to a net loss of $14.5 million, or $0.24 per share, for the three months ended September 30, 2023.

Basic and diluted net loss per share were $0.27 for the three months ended September 30, 2024, compared to a basic and diluted net loss per share of $0.24 for the three months ended September 30, 2023.

Longeveron provides an overview of the company and its business for the benefit of investors.

The company also provides financial information for the period ended September 30, 2024.

Longeveron is a clinical-stage biotechnology company developing cellular therapies for aging-related diseases.

The company's lead product candidate, Lomecel-B, is a cell therapy product candidate that is being developed for the treatment of aging-related diseases and conditions, such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).

Longeveron also provides a discussion of its product pipeline and clinical development programs.

Longeveron is a clinical-stage biotechnology company developing cellular therapies for aging-related diseases.

The company's lead product candidate, Lomecel-B, is a cell therapy product candidate that is being developed for the treatment of aging-related diseases and conditions, such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).

Longeveron is also developing other cell therapy product candidates for the treatment of aging-related diseases and conditions.

These product candidates are in various stages of development, and some of them are expected to enter clinical trials in the future.

Longeveron provides a discussion of its research and development activities for the period ended September 30, 2024.

The company also provides a discussion of its regulatory affairs activities for the period ended September 30, 2024.

Longeveron provides a discussion of its financial condition and results of operations for the period ended September 30, 2024.

The company also provides a discussion of its plans and objectives for the future.